{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:03:24Z","timestamp":1787317404382,"version":"build-2736575974"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.ahj.2020.07.005","type":"journal-article","created":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T02:06:08Z","timestamp":1594260368000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial"],"prefix":"10.1016","volume":"228","author":[{"given":"Yi","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanmin","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubing","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoliang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick J.","family":"Angiolillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaling","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ahj.2020.07.005_bb0005","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.ahj.2020.07.005_bb0010","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","article-title":"2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"68","author":"Levine","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2020.07.005_bb0015","doi-asserted-by":"crossref","unstructured":"Capodanno D, Alfonso F, Levine GN, Valgimigli M, Angiolillo DJ. ACC\/AHA versus ESC guidelines on dual antiplatelet therapy: JACC guideline comparison. J Am Coll Cardiol. 2018;72(23 Pt A):2915\u20132931.","DOI":"10.1016\/j.jacc.2018.09.057"},{"key":"10.1016\/j.ahj.2020.07.005_bb0020","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1001\/jama.2016.3775","article-title":"Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention","volume":"315","author":"Yeh","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ahj.2020.07.005_bb0025","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials","volume":"389","author":"Costa","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2020.07.005_bb0030","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1016\/j.jacc.2016.02.064","article-title":"Coronary thrombosis and major bleeding after PCI with drug-eluting stents: Risk scores from PARIS","volume":"67","author":"Baber","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.ahj.2020.07.005_bb0035","doi-asserted-by":"crossref","DOI":"10.1111\/1755-5922.12441","article-title":"Predicting long-term ischemic events using routine clinical parameters in patients with coronary artery disease: the OPT-CAD risk score","volume":"36","author":"Han","year":"2018","journal-title":"Cardiovasc Ther"},{"issue":"10073","key":"10.1016\/j.ahj.2020.07.005_bb0040","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0140-6736(17)30591-3","article-title":"Tailoring duration of DAPT with risk scores","volume":"389","author":"Capodanno","year":"2017","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.ahj.2020.07.005_bb0045","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1016\/j.jacc.2013.07.101","article-title":"Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding","volume":"62","author":"Tantry","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"10.1016\/j.ahj.2020.07.005_bb0050","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1409312","article-title":"Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents","volume":"371","author":"Mauri","year":"2014","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ahj.2020.07.005_bb0055","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ahj.2020.07.005_bb0060","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ijcard.2018.02.095","article-title":"Duration of dual antiplatelet therapy and outcome in patients with acute coronary syndrome undergoing percutaneous revascularization: a meta-analysis of 11 randomized trials","volume":"264","author":"Verdoia","year":"2018","journal-title":"Int J Cardiol"},{"issue":"8","key":"10.1016\/j.ahj.2020.07.005_bb0065","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41569-018-0049-1","article-title":"Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention","volume":"15","author":"Capodanno","year":"2018","journal-title":"Nat Rev Cardiol"},{"issue":"10151","key":"10.1016\/j.ahj.2020.07.005_bb0070","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","volume":"392","author":"Vranckx","year":"2018","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.ahj.2020.07.005_bb0075","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/jama.2019.8145","article-title":"Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial","volume":"321","author":"Watanabe","year":"2019","journal-title":"JAMA"},{"issue":"24","key":"10.1016\/j.ahj.2020.07.005_bb0080","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1001\/jama.2019.8146","article-title":"Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial","volume":"321","author":"Hahn","year":"2019","journal-title":"JAMA"},{"issue":"21","key":"10.1016\/j.ahj.2020.07.005_bb0085","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without aspirin in high-risk patients after PCI","volume":"381","author":"Mehran","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ahj.2020.07.005_bb0090","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.jacc.2015.06.1323","article-title":"Incidence, predictors, and impact of post-discharge bleeding after percutaneous coronary intervention","volume":"66","author":"G\u00e9n\u00e9reux","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"10.1016\/j.ahj.2020.07.005_bb0095","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.ahj.2020.07.005_bb0100","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/j.jacc.2012.08.001","article-title":"Third universal definition of myocardial infarction","volume":"60","author":"Thygesen","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"10.1016\/j.ahj.2020.07.005_bb0105","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials: a case for standardized definitions","volume":"115","author":"Cutlip","year":"2007","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/j.ahj.2020.07.005_bb0110","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/j.jacc.2006.11.044","article-title":"Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives","volume":"49","author":"Angiolillo","year":"2007","journal-title":"J Am Coll Cardiol"},{"issue":"16","key":"10.1016\/j.ahj.2020.07.005_bb0115","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.jcin.2019.03.034","article-title":"Updated expert consensus statement on platelet function and genetic testing for guiding p2y12 receptor inhibitor treatment in percutaneous coronary intervention","volume":"12","author":"Sibbing","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"issue":"27","key":"10.1016\/j.ahj.2020.07.005_bb0120","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/eurheartj\/ehv104","article-title":"Bleeding and stent thrombosis on P2Y12-inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention","volume":"36","author":"Aradi","year":"2015","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.ahj.2020.07.005_bb0125","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1161\/CIRCINTERVENTIONS.113.000412","article-title":"Stent thrombosis with second-generation drug-eluting stents compared with bare-metal stents: network meta-analysis of primary percutaneous coronary intervention trials in ST-segment-elevation myocardial infarction","volume":"7","author":"Philip","year":"2014","journal-title":"Circ Cardiovasc Interv"},{"issue":"8","key":"10.1016\/j.ahj.2020.07.005_bb0130","doi-asserted-by":"crossref","first-page":"942","DOI":"10.4244\/EIJV10I8A161","article-title":"Impact of technological developments in drug-eluting stents on patient-focused outcomes: a pooled direct and indirect comparison of randomised trials comparing first- and second-generation drug-eluting stents","volume":"10","author":"Colmenarez","year":"2014","journal-title":"EuroIntervention"},{"issue":"4\u20135","key":"10.1016\/j.ahj.2020.07.005_bb0135","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.pcad.2017.12.004","article-title":"Evolution of coronary stent technology and implications for duration of dual antiplatelet therapy","volume":"60","author":"Moon","year":"2018","journal-title":"Prog Cardiovasc Dis"},{"issue":"12","key":"10.1016\/j.ahj.2020.07.005_bb0140","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.hlc.2017.01.008","article-title":"Improving guideline compliance in australia with a national percutaneous coronary intervention outcomes registry","volume":"26","author":"Eccleston","year":"2017","journal-title":"Heart Lung Circ"},{"issue":"8","key":"10.1016\/j.ahj.2020.07.005_bb0145","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1161\/CIRCULATIONAHA.106.612812","article-title":"Adverse impact of bleeding on prognosis in patients with acute coronary syndromes","volume":"114","author":"Eikelboom","year":"2006","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.ahj.2020.07.005_bb0150","doi-asserted-by":"crossref","first-page":"e1841","DOI":"10.4244\/EIJ-D-17-00723","article-title":"Short- and long-term mortality following bleeding events in patients undergoing percutaneous coronary intervention: insights from four validated bleeding scales in the CHAMPION trials","volume":"13","author":"Vaduganathan","year":"2018","journal-title":"EuroIntervention"},{"issue":"3","key":"10.1016\/j.ahj.2020.07.005_bb0155","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1161\/CIRCULATIONAHA.119.040167","article-title":"Defining high bleeding risk in patients undergoing percutaneous coronary intervention","volume":"140","author":"Urban","year":"2019","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.ahj.2020.07.005_bb0160","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1016\/j.jacc.2017.02.029","article-title":"Bleeding-related deaths in relation to the duration of dual-antiplatelet therapy after coronary stenting","volume":"69","author":"Palmerini","year":"2017","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.ahj.2020.07.005_bb0165","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1016\/j.amjcard.2008.07.063","article-title":"Impact of \"nuisance\" bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation","volume":"102","author":"Roy","year":"2008","journal-title":"Am J Cardiol"},{"issue":"5","key":"10.1016\/j.ahj.2020.07.005_bb0170","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.ahj.2010.01.016","article-title":"Incidence, correlates, and clinical impact of nuisance bleeding after antiplatelet therapy for patients with drug-eluting stents","volume":"159","author":"Ben-Dor","year":"2010","journal-title":"Am Heart J"},{"issue":"20","key":"10.1016\/j.ahj.2020.07.005_bb0175","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1161\/CIRCULATIONAHA.117.031164","article-title":"International expert consensus on switching platelet P2Y12 receptor-inhibiting therapies","volume":"136","author":"Angiolillo","year":"2017","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ahj.2020.07.005_bb0180","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/CM9.0000000000000047","article-title":"De-escalation of anti-platelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a narrative review","volume":"132","author":"Han","year":"2019","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.ahj.2020.07.005_bb0185","first-page":"1","article-title":"De-escalation versus standard dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis","author":"Guo","year":"2019","journal-title":"Platelets"},{"key":"10.1016\/j.ahj.2020.07.005_bb0190","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/j.jacc.2008.08.002","article-title":"ACCF\/ACG\/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents","volume":"52","author":"Bhatt","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.ahj.2020.07.005_bb0195","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-026053","article-title":"Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-StudY (GLASSY)","volume":"9","author":"Leonardi","year":"2019","journal-title":"BMJ Open"},{"issue":"17","key":"10.1016\/j.ahj.2020.07.005_bb0200","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.4103\/0366-6999.239306","article-title":"Impact of baseline bleeding risk on efficacy and safety of ticagrelor versus clopidogrel in chinese patients with acute coronary syndrome undergoing percutaneous coronary intervention","volume":"131","author":"Wang","year":"2018","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"10.1016\/j.ahj.2020.07.005_bb0205","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.115.002816","article-title":"Clopidogrel versus aspirin as an antiplatelet monotherapy after 12-month dual-antiplatelet therapy in the era of drug-eluting stents","volume":"9","author":"Park","year":"2016","journal-title":"Circ Cardiovasc Interv"},{"issue":"Suppl. 1","key":"10.1016\/j.ahj.2020.07.005_bb0210","first-page":"579","article-title":"Impact of dual antiplatelet therapy duration on 1-year clinical outcomes in diabetic patients with acute coronary syndrome undergoing percutaneous coronary intervention: Insights from the real-world OPT-CAD study","volume":"95","author":"Li","year":"2020","journal-title":"Catheter Cardiovasc Interv"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870320302118?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002870320302118?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T09:57:50Z","timestamp":1762077470000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002870320302118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":42,"alternative-id":["S0002870320302118"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2020.07.005","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Extended antiplatelet therapy with clopidogrel alone versus clopidogrel plus aspirin after completion of 9- to 12-month dual antiplatelet therapy for acute coronary syndrome patients with both high bleeding and ischemic risk. Rationale and design of the OPT-BIRISK double-blinded, placebo-controlled randomized trial","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2020.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}